

## **Dr Matthew Baker Joins Celentyx Ltd as VP Immunology & Oncology**

**BIRMINGHAM, UK – 1<sup>st</sup> December, 2016** - Celentyx Ltd, UK ("Celentyx") a pharmaceutical company with a focus on immune system mediated diseases, announced today that Dr Matthew Baker is joining the management team as VP, Immunology & Oncology.

Dr Baker brings a wealth of expertise to Celentyx and will take a lead role in the development of the Celentyx's ImmuKnowlogy™ research services.

"Celentyx is truly at the forefront of research investigating diseases involving the immune system," said Dr Baker. "I'm looking forward to working with the team to maximise conversion of Celentyx's tremendous potential".

Dr Baker was most recently the Chief Scientific Officer of Abzena plc, having co-founded Antitope Ltd. in 2004 and served as its Chief Scientific Officer and Chief Executive Officer before the successful trade sale. Prior to this, he served as Vice President for Biologics Discovery at Biovation Ltd. Dr. Baker has a background in B and T cell immunology and completed post-doctoral positions in Cambridge, UK, after obtaining his PhD in cellular immunology at the University of Birmingham.

"We're delighted to bring Matt's expertise and vast experience to Celentyx," commented Celentyx's CEO and co-Founder, Professor Nicholas Barnes. "He has been a vital part of a number of successful companies and we are confident he will further boost Celentyx's impressive growth as we embark on expanding both our research services and drug development pipeline".

### **About Celentyx Ltd**

Celentyx is a pharmaceutical R&D and service company with a focus on diseases relevant to the human immune system. Utilising both healthy donor and patient tissues and cells, Celentyx supports inflammation, auto-immunity and immuno-oncology discovery projects

Celentyx's ImmuKnowlogy™ research services allows rapid analysis of drug action on human immune cells and tissues at the highest levels of resolution, enabling partners to identify new development paths for clinical-stage drug candidates, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system. The company has established partnerships with a number of medium and large pharmaceutical companies.

For more information, please visit Celentyx's website at [www.celentyx.com](http://www.celentyx.com) or contact:

Catherine Brady, PhD  
Chief Operating Officer  
E-mail: [catherine.brady@celentyx.com](mailto:catherine.brady@celentyx.com)